Smoothing the Path to Drug Development with Accurate Clinical Data
Drug development is a long, costly, and complex process. At its core lies a critical question: How does a drug affect the body—and how does the body respond? The answers are derived from well-structured pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) investigations conducted in both preclinical and clinical studies.
This whitepaper highlights the importance of accurate, standardized clinical data in reducing delays, overcoming bottlenecks, and ensuring that promising therapies progress smoothly toward regulatory approval.
Why PK, PD, and TK Data Matter
- Pharmacokinetics (PK): Describes how the body absorbs, distributes, metabolizes, and excretes (ADME) a drug—essentially, what the body does to the drug.
- Toxicokinetics (TK): Focuses on systemic exposure at different dose levels, linking toxicity findings to drug concentrations.
- Pharmacodynamics (PD): Explains what the drug does to the body—its mechanism of action, magnitude of response, and duration.
Together, PK, PD, and TK provide a complete view of safety and efficacy. Regulatory agencies rely on these datasets to establish safe starting doses and assess the benefit-risk balance.
Challenges in Translating Data
While methodologies have advanced, one major hurdle remains: translating data from animals to humans, and from in vitro to in vivo models. These translations often cause delays in the development process.
In addition, toxicology data is frequently fragmented—scattered across reports, tables, and figures. Without standardization, these inconsistencies make it difficult to draw reliable conclusions and may slow regulatory approval.
NOAEL and Data Reliability
The No-Observed-Adverse-Effect-Level (NOAEL) defines the highest tested dose without adverse effects and is central to first-in-human (FIH) dosing. However, deriving NOAEL requires curated, consistent data. Errors or variability in datasets can delay decision-making and introduce risk.
The Value of Data Standardization
PK/PD/TK datasets are only as valuable as their quality and consistency. Standardizing and digitizing toxicology data transforms unstructured reports into reliable, analysis-ready outputs. This enables faster study reviews, supports regulatory compliance, and ensures insights are not lost across diverse datasets.
Real-World Impact
A leading pharmaceutical company partnered with Excelra to digitize and structure 65 investigator brochures (IBs) across multiple therapeutic areas. Our team extracted unstructured PK/PD/TK data, standardized hundreds of variables, and delivered a consolidated dataset spanning key domains such as clinical, TK, safety, and NOAEL.
The result: a comprehensive dataset that accelerated preclinical review, improved dose selection, and supported regulatory submissions.
Why Read This Whitepaper?
This whitepaper provides:
- A clear overview of PK, PD, and TK studies.
- Insights into bottlenecks that delay drug development.
- Practical approaches for standardizing toxicology data.
- A case study demonstrating real-world impact.
If your teams handle complex preclinical and clinical datasets, this resource will help you improve reliability, reduce inefficiencies, and move faster toward regulatory milestones.
Download the Whitepaper to learn how accurate, standardized PK/PD/TK data smooths the path to safer, faster drug development.
Download '.pdf' Format of the whitepaper.
